AzTrials
AzTrials

Revised Medication Guide FormatsNCT01731405

Consumer Understanding and Use of Medication Guides

An observational study of Revised Medication Guide Formats, run by Northwestern University at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine the potential efficacy of three revised Medication Guide layouts to increase consumers' comprehension Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Revised Medication Guide Formats
How many people
600 participants
Where
2 sitesUnited States
Study dates
Nov 2012to Feb 2014
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: We are recruiting from 2 primary care clinics.

Who may be able to join

  • 18 years or older
  • English speaking
  • Physically in the primary care clinic

Who cannot join

  • Under 18 years old
  • Non-English speaking
  • An uncorrectable hearing or a visual impairment which would hinder participants' ability to view the materials
  • Too ill to participate
  • Moderate to severe cognitive impairments

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Northwestern Medical Faculty Foundation

    Chicago, Illinois, 60611

  • Primary Care Plus

    Chicago, Illinois, 60636

Other trials in United States

About this study

The purpose of this study is to determine the potential efficacy of three revised Medication Guide layouts to increase consumers' comprehension

Read the detailed description

'Medication Guides' (Med Guides) are industry-developed documents that have been required by the Food and Drug Administration (FDA) to be issued to consumers for prescription medications that have been viewed to possess "serious and significant public health concerns" since 1998.1,2 These materials for consumers are intended to 1) provide specific dosing administration instructions that could prevent serious adverse effects associated with taking the medication, 2) warn individuals about significant health risks that could affect one's decision to take the medication, or 3) underscore the importance of taking the prescribed medication to the patient's health, and the need for proper adherence.

Despite their potential value in communicating safe and appropriate medication use, problems are clearly evident with the current template for Med Guides. Research conducted by this team in 2006 showed that the majority, if not all Med Guides dispensed with prescribed medicines are too complex and written at a reading grade level not suitable for the majority of patients to comprehend. As a result, these materials are usually ignored by consumers.3 Further research by this team investigating consumers' ability to process and correctly understand content contained in existing Med Guides found that, across all literacy levels, current Med Guides are poorly understood and ineffective in conveying safety information. Patients with low literacy comprehended significantly less, proving yet again that industry standards must be applied to improve these documents.

It is clear that the current guidance for Medication Guide development is insufficient, and the FDA is working to change that. Both the FDA and this research team have proposed multiple new Medication Guide formats, most of which are one-page cover sheets that highlight the most important information of the medication. To examine these new prototypes, this research team conducted six focus groups to obtain consumer-based feedback, and then evaluated three of the prototypes in an eye tracking study. Using the collective data from these two consumer-based studies, the investigators have further developed patient-centered and evidence-based Med Guide prototypes that will be more user-friendly, clear, usable, and low literacy appropriate.

In a cross-sectional, controlled trial, the investigators will investigate consumers' ability to process and correctly understand content contained in each of these top three new, redesigned prototypes.

The purpose of this research is to better understand how well people with varying levels of literacy understand information contained in three newly designed Med Guides. Through an in-person interview, the investigators aim to test consumers' ability to comprehend information contained in the guides by asking them retrieval and inference questions over the guides' content. This will allow us to compare the three formats against each other to see which prototype is most efficient in conveying the important information it is intended to convey. The investigators will recruit a total of 600 participants from general internal medicine clinics here in Chicago (Northwestern clinic = 300 participants and University of Illinois Chicago = 300 participants. A UIC RA will be responsible for this recruitment and will submit their own IRB for review).

This trial will field test our enhanced prototypes and allow us to compare them to each other, showing which format is best understood, especially in participants with low literacy.

Keywords
Medication Guides, FDA, Prototype, Format

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01731405
Study groupRoleWhat they receive
Formats A,B,C; medicines Ritalin, Morphine Sulfate, AranespAll patients will see all 3 different formats of the Medication Guide prototypes. They will also see information for the same drugs, in the same order - Ritalin, Morphine Sulfate, and Aranesp. All participants see all the formats, the only thing that changes by participant is which format is in each medication. There will be 6 different randomized orders - A,B,C; A,C,B; B,C,A; B,A,C; C,A,B; C,B,A. So for example, A,B,C participants would see Ritalin in format A, Morphine Sulfate in format B, and Aranesp in format C.
There is not another groupNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Functional Understanding and Comprehension

    The primary outcome is to measure which of the three different formats of Medication Guides has the best participant comprehension, which we will assess based on total correct points out of total possible points.

    Measured: 30 minute interview

Secondary outcomes (2)
  1. Health Literacy (REALM)

    The REALM (Rapid Estimate of Adult Health Literacy in Medicine) is a word recognition test designed to provide a valid and quick assessment of participant health literacy.

    Measured: 30 minutes

  2. Participant Characteristics

    Basic demographic characteristics (age, sex, race/ethnicity), socioeconomic information (education, household income), health status information (self-reported overall health), and recent medication use will be collected by self report.

    Measured: 30 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Nov 2012 (estimated)
  2. Study startNov 2012
  3. Primary completionMar 2013
  4. Study completionFeb 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Enrolment
600 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01731405
Sponsor's protocol ID
ABT-5599
Other IDs
Abbott Laboratories
Status last verified
Apr 2014
First submitted
16 Nov 2012
Last updated
9 Apr 2014
Results posted
No
Data monitoring committee
Yes

Publications

  • Tsfasman IM, Starovoitov II, Ziakun AM, Skriabin GK. [Study of the initial reaction of enzymatic oxidation of 1,8-dimethylnaphthalene]. Biokhimiia. 1976 May;41(5):864-8. Russian.

    PubMed 15641
  • Wolf MS, King J, Wilson EA, Curtis LM, Bailey SC, Duhig J, Russell A, Bergeron A, Daly A, Parker RM, Davis TC, Shrank WH, Lambert B. Usability of FDA-approved medication guides. J Gen Intern Med. 2012 Dec;27(12):1714-20. doi: 10.1007/s11606-012-2068-7. Epub 2012 May 8.

    PubMed 22566170
  • Wallace LS, Roskos SE, Weiss BD. Readability characteristics of consumer medication information for asthma inhalation devices. J Asthma. 2006 Jun-Jul;43(5):375-8. doi: 10.1080/02770900600709856.

    PubMed 16801142
  • Safonova TIa, Shelkovskii VI. [Nicotinamide coenzyme level in erythrocytes in children with cerebral paralysis]. Pediatriia. 1977 May;(5):71-3. No abstract available. Russian.

    PubMed 17846
  • Bull C, Goncher G, Deutschman CS, Hoffman BM. Source of residual Bohr effect in hemoglobin oxidation. J Biol Chem. 1977 May 25;252(10):3128-30.

    PubMed 16881
  • Wolf MS, Bailey SC, Serper M, Smith M, Davis TC, Russell AL, Manzoor BS, Belter L, Parker RM, Lambert B. Comparative effectiveness of patient-centered strategies to improve FDA medication guides. Med Care. 2014 Sep;52(9):781-9. doi: 10.1097/MLR.0000000000000182.

    PubMed 25119953

Questions about this trial

What is this clinical trial studying?

An observational study of Revised Medication Guide Formats, run by Northwestern University at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Functional Understanding and Comprehension (time frame: 30 minute interview). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01731405, which also lists 6 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in